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Abstract: Background: Coronary artery involvement is seen in approximately 15–20% of
children with Kawasaki disease. There is conflicting literature regarding the clinical and
laboratory findings associated with coronary artery involvement. In this retrospective
study, we attempt identification of predictive factors for coronary artery involvement at our
institute and review the existing literature. Methods and results: A review of 203 patients
(65% males) with Kawasaki disease was performed, of whom 33 (16.3%) had coronary
artery involvement. High erythrocyte sedimentation rate, high platelet count, low hematocrit,
low albumin levels, and refractory Kawasaki disease showed significant association with
coronary artery involvement. High erythrocyte sedimentation rate and refractory Kawasaki
disease were found to be independent predictors of coronary artery involvement. Review
of literature suggested a wide range of coronary involvement (<5% to >60%), and highly
conflicting clinical and laboratory associations. Conclusion: It remains difficult to accurately
determine risk of coronary artery involvement, although some laboratory markers may
provide information that is helpful for parental counseling and clinical follow up. Future
identification of novel biomarkers and host predispositions may further our understanding
of coronary artery risks and help personalize therapy for Kawasaki disease.
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1. Introduction
Coronary artery involvement is the most important complication of Kawasaki disease and is seen in
approximately 15–20% of affected [1,2]. Past efforts at using clinical and laboratory parameters to
predict coronary artery involvement in Kawasaki disease yielded inconsistent results. Extremes of age,
longer duration of fever, higher white blood cell count, lower or higher platelet count, higher C-reactive
protein, low hematocrit, and low serum albumin have been reported to be associated with coronary
artery involvement in Kawasaki disease [2,3]. A number of scoring systems have attempted to guide
decision-making for pharmacotherapy of Kawasaki disease based on risk of coronary artery involvement.
These have however not been widely adopted due to complex nature and/or low accuracy [4–6].
Because of the imperfect performance of scoring systems, the 2004 American Heart Association
guidelines recommend that all patients diagnosed with Kawasaki disease be treated with intravenous
immunoglobulin [7].
Published literature also reports a wide range of coronary artery involvement rate in Kawasaki
disease from less than 5% to over 60% [5,8]. Much of this variability stems from the varying definitions
of coronary artery involvement [9]. The first widely used definition of coronary artery involvement in
Kawasaki disease was proposed by the Japanese Ministry of Health. It classified coronary arteries as
abnormal if the internal lumen diameter was >3 mm in children <5 years old or >4 mm in children
≥5 years old; if the internal diameter of a segment measured ≥1.5 times that of an adjacent segment;
or if the coronary lumen was clearly irregular [10]. Coronary artery that appeared dilated on
echocardiography but failed to meet these criteria were subjectively called ectatic prior to publication
of body surface area adjusted z-scores that are now commonly used [11,12]. It has been shown that
use of coronary artery z-scores can identify lesions that may have been previously misclassified as
normal [9]. In one large report of over 2,500 patients in the US, the proportion of patients with
coronary artery aneurysms increased from 10.0% in 1994 to 17.8% in 2003 [13]. Although the initial
pharmacological treatment may not differ based on presence or absence of mild coronary involvement,
an accurate definition of coronary involvement is important for the purpose of patient counseling and
follow up.
In the present study we retrospectively analyze data from 203 children with Kawasaki disease at our
institute for coronary artery involvement and attempt identification of its predictive clinical and
laboratory parameters. We also present a pertinent review of existing literature.
2. Materials and Methods
Data used were collected in conjunction with a study of the impact of the 2004 American Heart
Association guidelines on Kawasaki disease [14]. A retrospective review of medical records was
performed for patients with Kawasaki disease (International Classification of Diseases 9th revision
code 446.1) between July 2000 and June 2002, and between July 2007 and June 2009. Patients were
included only if they had adequate medical records for review and received at least one dose of

Diagnostics 2013, 3

234

intravenous immunoglobulin. The study was approved by the institutional review board. Patients’ age,
sex, days of fever at diagnosis, presence or absence of each of the principal clinical criteria (rash,
conjunctivitis, extremity changes, oral changes, and cervical lymphadenopathy) and laboratory values
were collected. Patients with <4 principal clinical criteria were classified as having incomplete
Kawasaki disease. All laboratory values were collected before the administration of intravenous
immunoglobulin and included white blood cell count, hematocrit, platelet count, C-reactive protein,
erythrocyte sedimentation rate, albumin, alanine aminotransferase, and urine leukocyte count. If more
than one lab result was available prior to intravenous immunoglobulin administration, the most abnormal
value was recorded. Patients were considered to have coronary artery abnormalities due to Kawasaki
disease if either any coronary artery segment had a z-score of ≥2.5, adjusted for body surface area, or if
they met the Japanese Ministry of Health criteria for coronary artery abnormality. Z-scores were
derived for the left main, right proximal, and proximal left anterior descending coronary arteries using
equations previously published from our echocardiography database [12]. Refractory Kawasaki disease
was defined as persistence of fever after one dose of intravenous immunoglobulin and administration
of additional intravenous immunoglobulin or use of corticosteroids or TNF-alpha blockers. We did not
use a specific time frame for fever persistence after intravenous immunoglobulin and instead left it to
the discretion of the treating physician.
Statistical analysis: Continuous variables were summarized as mean ± standard deviations when
normally distributed and as medians and interquartile ranges when nonparametric. Normality of the
data was assessed using Shapiro-Wilk test and visual inspection of histograms. Fisher’s exact test
and chi-square test were used for comparing proportions as appropriate. Univariable analyses were
performed using unpaired t test or Mann Whitney U test to determine whether duration of fever, age,
white blood cell count, hematocrit, platelet count, C-reactive protein, erythrocyte sedimentation rate,
albumin, alanine aminotransferase or urine white cell count discriminated between patients with and
without coronary artery involvement. To identify independent predictors, binary logistic regression
models were constructed using the laboratory variables that had been selected by univariable analysis.
The discriminatory capacity of the regression model was assessed using the area under the
receiver-operating-characteristics curve. Type I error was set at 0.05. All calculations were performed
using SPSS Statistics 17 for Windows (IBM Corporation, Armonk, NY, USA) or Open Office Calc
(openoffice.org v3.3.0 Oracle Inc., Redwood City, CA, USA).
3. Results
Of the 203 patients that met inclusion criteria, 65.0% were males. Median age of the study
population was 35 months (interquartile range 16–58 months) and duration of fever at diagnosis was
6 days (interquartile range 5–8 days). Coronary involvement was present in 33 (16.3%) patients.
Clinical and laboratory parameters in patients with and without coronary artery involvement are
presented in Table 1. Patients with coronary artery involvement had significantly higher erythrocyte
sedimentation rate and platelet count and lower hematocrit and albumin levels. The results of
multivariate binary logistic regression analysis of variables that were significantly different between
those with and without coronary artery involvement are shown in Table 2. Having refractory Kawasaki
disease and a high erythrocyte sedimentation rate were independently associated with coronary artery
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involvement. Goodness of fit of the regression model was confirmed with the Hosmer-Lemeshow test
(p value = 0.93), which indicated lack of deviation between the model and observed event rate. Area
under the curve for predicted probabilities was 0.82 (95% confidence interval 0.735–0.905, p < 0.001).
Among laboratory parameters, erythrocyte sedimentation rate had the strongest association with
coronary artery involvement and patients with erythrocyte sedimentation rate ≥80 mm (25.3%) had
4.2 times higher odds (95% confidence interval 2.1 to 10.7) of having coronary artery involvement as
compared to those with levels below 80 mm/h.
Table 1. Comparison of clinical and laboratory parameters between patients with and
without coronary artery involvement. Abbreviations: CA, coronary artery; IQR, interquartile
range; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood
cell; SD, standard deviation; ALT, alanine aminotransferase; HPF, high power field; KD,
Kawasaki disease (* p value ≤ 0.05 was considered statistically significant).
Male, %
Age, months, median (IQR)
Fever, days, median (IQR)
Extremity changes, %
Rash, %
Eyes, %
Oral, %
Lymphadenopathy, %
WBC, ×103 per cubic mm, median (IQR)
Hematocrit, %, mean (SD)
Platelets, ×103 per cubic mm, median (IQR)
CRP, mg/dL, median (IQR)
ESR, mm/hr, mean (SD)
Albumin, g/dL, mean (SD)
ALT, units/L, median (IQR)
Urine white cells per HPF, median (IQR)
Refractory KD, %
Incomplete KD, %

CA Involved (N = 33)
75.8
37 (10.5–61)
6 (5–9)
57.6
78.8
90.9
87.9
57.6
14.5 (11.1–18.6)
29.5 (4.7)
465 (295.5–670.5)
7.0 (3.6–16.1)
86.3 (37.8)
2.7 (0.6)
54 (28–87)
2 (0–8.5)
60.6
45.9

CA Normal (N = 170)
62.9
34.5 (16.8–55.5)
6 (5–8)
69.4
87.6
85.3
77.6
56.5
14.2 (10.1–17.3)
32.0 (3.4)
382 (282.3–484.8)
5.8 (2.6–10.4)
57.3 (26.7)
3 (0.6)
39.5 (27–83.5)
3 (0–14.8)
16.5
35.9

p value
0.16
0.98
0.39
0.18
0.18
0.58
0.18
0.91
0.54
0.01
0.05
0.31
<0.001
0.02
0.45
0.72
<0.001
0.33

*
*
*
*

*

Table 2. Results of multivariate binary regression analysis. Odds ratio favors coronary
artery involvement. Abbreviations: ESR, erythrocyte sedimentation rate (* p value ≤ 0.05
was considered statistically significant).
Platelets
ESR
Hematocrit
Albumin
Refractory Kawasaki disease

Odds Ratio
1.002
1.023
0.965
0.670
5.270

95% Confidence Interval
1.000
1.005
1.006
1.041
0.830
1.121
0.260
1.722
2.029
13.689

p value
0.10
0.01
0.64
0.41
<0.001

*

*

4. Discussion
In the present study, patients with Kawasaki disease and coronary artery involvement had higher
erythrocyte sedimentation rate and platelet count and lower hematocrit and albumin levels. A number
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of attempts have been made to devise predictive instruments for coronary artery involvement
in Kawasaki disease. The Harada score developed in Japan was perhaps the most widely used
decision-making tool for the use of intravenous immunoglobulin in Kawasaki disease prior to universal
treatment. Children who fulfilled 4 of the following criteria and were assessed within 9 days of onset
of illness were administered intravenous immunoglobulin: (1) white blood cell count > 12,000/mm3;
(2) platelet count < 350,000/mm3; (3) C-reactive protein > 3+; (4) hematocrit < 35%;
(5) albumin < 3.5 g/dL; (6) age ≤ 12 months; and (7) male sex. For children with <4 risk factors but
continuing acute symptoms, the risk score was reassessed daily [4]. In the United States, Beiser et al.
devised a predictive instrument for the development of coronary artery involvement. Risk factors used
in their instrument included baseline neutrophil and band counts, hemoglobin concentration, platelet
count, and temperature on the day after intravenous immunoglobulin infusion [5]. This tool had the
drawback of a low positive predictive value and fell out of use. Asai et al. proposed a scoring system
to predict coronary artery involvement based on 15 characteristics, each of which was given a score of
0, 1 or 2 [6]. This scoring system could not be widely adopted as the variables included chest
radiograph and electrocardiogram findings and serial measurements of labs; tests which are now not
routinely performed for Kawasaki disease.
Inflammatory changes in coronary arteries have been demonstrated in Kawasaki disease even in
the absence of aneurysms [15]. Early stages of arterial wall inflammation in Kawasaki disease are
characterized by edematous dissociation of the smooth muscle cells, endothelial swelling and
subendothelial edema; polymorphonuclear cell infiltration then ensues, which in turn sets the stage for
infiltration by mononuclear cells and lymphocytes [16,17]. In cases with ectasia or aneurysm
formation there is destruction of the internal elastic lamina and eventually fibroblastic proliferation,
followed by several weeks of scarring that may lead to stenosis. As coronary aneurysm formation
represents severe inflammation, one would logically expect laboratory markers of inflammation to be
higher in patients with visible coronary artery involvement. Gao et al. have reported association of
fibrinogen polymorphisms and high plasma fibrinogen levels with coronary artery involvement in
Kawasaki disease [18]. Fibrinogen is a major determinant of erythrocyte sedimentation rate and a high
erythrocyte sedimentation rate was found to have strong association with coronary involvement in the
present study. Despite the strong association with erythrocyte sedimentation rate, coronary involvement
was not associated with high C-reactive protein levels. Although both fibrinogen and C-reactive
protein levels rise in inflammation, they are not directly related proteins and this might explain lack of
coronary involvement and C-reactive protein levels in the present study. In addition, C-reactive protein
was not commonly performed at our center prior to 2002, it being obtained for 109 of the 203 enrolled
subjects. Our analysis may have hence lacked adequate power to detect a significant association
between C-reactive protein and coronary involvement.
Refractory Kawasaki disease, usually defined as persistent or recrudescent fever ≥36 h after
completion of the initial intravenous immunoglobulin infusion, is perhaps a sign of the most severe
form of inflammation and was found to have a strong association with coronary artery disease in the
present study [7]. Likewise, most other studies that have primarily focused on predicting refractoriness
of Kawasaki disease pointed towards a worse overall laboratory profile and a higher rate of coronary
artery involvement [19]. Numerous papers have compared abnormal laboratory findings in patients
with Kawasaki disease with and without coronary artery involvement. Table 3 presents some of these
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studies and demonstrates the existing ambiguity in this regard [2,4–6,8,13,20–41]. The finding that is
most consistently reported among these studies is a higher duration of fever (11 of 14 studies that
reported this variable). In the present study however, we did not find a significantly higher duration of
fever at diagnosis, in patients with coronary artery involvement. This difference is probably accounted
for by the difference in the timing of intravenous immunoglobulin. Our study group is relatively recent
as compared to many of the older studies wherein intravenous immunoglobulin might have been
withheld for a longer duration. The present study also did not find an association between coronary
artery involvement and younger age (in agreement with 8 of 16 studies that reported ages), male sex
(in agreement with 10 of 14 studies that reported sex), higher white blood cell count (in agreement
with 14 of 20 studies that reported white blood cell count), higher C-reactive protein level (in agreement
with 6 of 13 studies that reported C-reactive protein ) and higher alanine aminotransferase levels
(in agreement with 3 of 4 studies that reported alanine aminotransferase). On the other hand, in the
present study, coronary artery involvement was associated with a high erythrocyte sedimentation rate
(in agreement with 4 of 12 studies that reported erythrocyte sedimentation rate), high platelet count
(in agreement with 2 of 15 studies that reported platelet count), low hematocrit/hemoglobin (in
agreement with 5 of 15 studies that report this variable) and a low albumin level (in agreement with 9 of
14 studies that report this variable). These findings highlight the lack of a uniform pattern of
conventional laboratory changes in Kawasaki disease and need for better biomarkers to predict
coronary artery involvement.
Changes in these traditionally studied laboratory values reflect inflammation, vasculitis, endothelial
damage resulting in capillary leak, and tissue repair. Nontraditional laboratory markers such as B-type
natriuretic peptide levels, beta thymoglobulin and plasma clusterin have also been reported to predict
coronary artery involvement but still need to be tested on a larger scale [37,42,43]. Changes in the
level of hepcidin, a central modulator of inflammation associated anemia, are known to negatively
correlate with hemoglobin levels and are associated with coronary artery involvement in Kawasaki
disease [44]. Although the inflammatory marker levels do not seem to reliably identify those that
might have coronary artery involvement, they are invariably elevated in patients with Kawasaki
disease. This points towards presence of factors other than the severity of inflammation that play a role
in determination of coronary artery involvement. In the recent years a number of genetic markers
including certain genetic polymorphisms, specific genes, human lymphocyte antigen types, calcium
dependent NFAT signaling, caspase-3, and TGF beta genes have been associated with coronary artery
involvement in Kawasaki disease [45–57]. Yamamura et al. have recently reported higher risk of
coronary involvement in BB blood group genotype [58]. Future studies will need to identify novel
markers and host characteristics to supplement clinical and traditional laboratory parameters to guide
the clinical decisions about the use of efficacious, but expensive and potentially harmful therapies for
Kawasaki disease. Identifying this risk of coronary artery involvement may be of particular importance
in those children who continue to have fever despite one or two doses of intravenous immunoglobulin
and are considered candidates for newer therapies including TNF-alpha blockers and other biomodulators.
This study is limited by its retrospective nature and relatively small sample size. By retrospective
design, it was not possible to record laboratory results on a uniform day of illness. We therefore utilized
the most abnormal laboratory result prior to IVIG administration which has the potential to lead to bias
due to extreme values. Although we performed a detailed review of literature, we did not do a formal
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meta-analysis of the question. Given the absence of a detailed national Kawasaki disease database to
perform a uniform large-scale analysis, a formal meta-analysis may support these initial findings.
Table 3. Variability in reported clinical and laboratory findings associated with coronary
artery involvement in Kawasaki disease. Yes indicates presence of association with coronary
involvement; No, absence of association; Up and down arrows indicate high or low values
of the laboratory parameters; Fever indicates longer duration of fever. In the platelets
column, High indicates association of coronary involvement with a higher platelet count and
Low indicates association of coronary involvement with a low platelet count; Abbreviations:
CAI, coronary artery involvement; KD, Kawasaki disease; iKD, incomplete KD; rKD,
refractory KD; ESR, erythrocyte sedimentation rate; WBC, white blood cell; N, Neutrophil
count; Plt, platelet count; CRP, C-reactive protein; ALT, alanine aminotransferase; Hct,
hematocrit/hemoglobin. * In this study the white blood cell count, platelet count and
C-reactive protein significantly increased after intravenous immunoglobulin in patients with
KD but levels were similar to those without coronary involvement prior to IVIG, # In this
study the labs were obtained after intravenous immunoglobulin therapy. @ This study is a
meta analysis of Chinese literature. & These two studies do not specify the duration of fever,
however report the duration of illness/symptoms prior to IVIG administration. This duration
is likely to be same or similar to duration of fever in most cases; however this may not be
true for all patients.
Study

n

CAI%

↓Age

Fever

Asai et al. [6]

102

14.7

Yes

Yes

Ishihara et al.[20]

130

23.8

Yes

Yes

Koren et al. [21]

163

15.0

No

Yes

Nakano et al. [22]

78

20.5

No

Nakano et al. [23]

22

36.4

Ichida et al. [25]

110

22.7

Yes

Yes

No

Yes

No

High

No

Daniels et al. [26]

77

12

No

Yes

No

No

No

No

Yes

Harada et al. [4]

258

13.2

Yes

Yes

Low

Lu et al. [27]

70

21

760

4.3

193

12.2

Morikawa et al. [29] #

451

6.9

Nomura et al. [30]

125

15.2

Honkanen et al. [32]

344

28.5

Yes

Belay et al. [13]

2,798

12.9

Yes

Durongpisitkul et al. [34]

432

14.5

Kim et al. [35]

285

6.7

No

Yes

McCrindle et al. [2]

190

26

Yes

Yes

Chaiyarak et al. [33]

96

28.9

Kim et al. [36]

475

33.5

Beiser et al. [5]
Mori et al. [28] *

&

iKD

rKD

↑ESR

↑WBC

Yes

Yes

No

No

Yes

No

Yes

No

No

No

No

No

No

No

Male

No

↑N

Plt

↑CRP

↑ALT

No

↓Hct ↓Albumin
No

Yes

No

Yes

Yes

No

No

Yes

Yes

No

Yes

Yes

Yes

Yes
Yes

Low

No

No

No

Yes

Yes

Yes

No

No

No

Yes

No
Yes

No
Yes

Yes

No

Yes

No

Yes

Yes

Yes

Yes

No

No

Yes

Yes
Yes
Yes

Yes

Yes

Yes

No

Yes
No

Yes

No

Yes

Yes
No

No

Yes

Yes

Yes

No

No

No

No

No

No

Yes
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Study
Kaneko et al [37]
Chen et al. [38]

&

@

n

CAI%

↓Age

Fever

43

14.0

No

No

iKD

rKD

Male

No

No

8,330

↑ESR

↑WBC

Yes

No

380

31.6

Yes

Yes

Caballero-Mora [40]

76

15.7

No

No

Weng et al. [41]

216

37.5

No

Zhang et al. [8]

553

63.3

Yes

No

Yes

No
No

Plt

No

Tremoulet et al. [39]

Yes

↑N

No
No

No

↑CRP

↑ALT

↓Hct ↓Albumin

No

No

Yes High

Yes

No

Yes

No

No

Yes

No

No

Low

No

No

No

No

No

No

No

Yes

5. Conclusion
Based on proven efficacy and reasonable safety profile of intravenous immunoglobulin, and review
of literature, the authors agree with the 2004 American heart association guidelines that all patients
with Kawasaki disease should receive therapy with intravenous immunoglobulin irrespective of
laboratory changes. It remains difficult to accurately determine risk of coronary artery involvement.
Future identification of novel biomarkers and host predispositions may further our understanding of
coronary artery risks and help personalize therapy for Kawasaki disease.
References
1.

2.

3.

4.
5.
6.
7.

8.

Sabharwal, T.; Manlhiot, C.; Benseler, S.M.; Tyrrell, P.N.; Chahal, N.; Yeung, R.S.M.;
McCrindle, B.W. Comparison of factors associated with coronary artery dilation only versus
coronary artery aneurysms in patients with Kawasaki disease. Am. J. Cardiol. 2009, 104,
1743–1747.
McCrindle, B.W.; Li, J.S.; Minich, L.L.; Colan, S.D.; Atz, A.M.; Takahashi, M.; Vetter, V.L.;
Gersony, W.M.; Mitchell, P.D.; Newburger, J.W. Coronary artery involvement in children with
Kawasaki disease risk factors from analysis of serial normalized measurements. Circulation 2007,
116, 174–179.
Song, D.; Yeo, Y.; Ha, K.; Jang, G.; Lee, J.; Lee, K.; Son, C.; Lee, J. Risk factors for Kawasaki
disease-associated coronary abnormalities differ depending on age. Eur. J. Pediatr. 2009, 168,
1315–1321.
Harada, K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr. Jpn. 1991,
33, 805–810.
Beiser, A.S.; Takahashi, M.; Baker, A.L.; Sundel, R.P.; Newburger, J.W. A predictive instrument
for coronary artery aneurysms in Kawasaki disease. Am. J. Cardiol. 1998, 81, 1116–1120.
Asai, T. Evaluation method for the degree of seriousness in Kawasaki disease. Pediatr. Int. 1983,
25, 170–175.
Newburger, J.W.; Takahashi, M.; Gerber, M.A.; Gewitz, M.H.; Tani, L.Y.; Burns, J.C.;
Shulman, S.T.; Bolger, A.F.; Ferrieri, P.; Baltimore, R.S.; et al. Diagnosis, treatment, and
long-term management of Kawasaki disease. Circulation 2004, 110, 2747–2771.
Zhang, X.; Zhang, Z.; Liu, S.; Sun, J. Epidemiologic survey of Kawasaki disease in Jilin from
1999 through 2008. Pediatr. Cardiol. 2012, 33, 272–279.

Diagnostics 2013, 3
9.

10.

11.
12.

13.

14.

15.

16.
17.

18.

19.

20.

21.
22.

23.

240

De Zorzi, A.; Colan, S.D.; Gauvreau, K.; Baker, A.L.; Sundel, R.P.; Newburger, J.W. Coronary
artery dimensions may be misclassified as normal in Kawasaki disease. J. Pediatr. 1998, 133,
254–258.
Research Committee on Kawasaki Disease. Report of the Subcommittee on Standardization of
Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki Disease; Ministry of
Health and Welfare: Tokyo, Japan, 1984.
Dallaire, F.; Dahdah, N. New equations and a critical appraisal of coronary artery Z scores in
healthy children. J. Am. Soc. Echocardiogr. 2011, 24, 60–74.
Olivieri, L.; Arling, B.; Friberg, M.; Sable, C. Coronary artery Z score regression equations
and calculators derived from a large heterogeneous population of children undergoing
echocardiography. J. Am. Soc. Echocardiogr. 2009, 22, 159–164.
Belay, E.D.; Maddox, R.A.; Holman, R.C.; Curns, A.T.; Ballah, K.; Schonberger, L.B. Kawasaki
syndrome and risk factors for coronary artery abnormalities. Pediatr. Infect. Dis. J. 2006, 25,
245–249.
Ghelani, S.J.; Sable, C.; Wiedermann, B.L.; Spurney, C.F. Increased incidence of incomplete
kawasaki disease at a pediatric hospital after publication of the 2004 American heart association
guidelines. Pediatr. Cardiol. 2012, 33, 1097–1103.
Fujiwara, T.; Fujiwara, H.; Nakano, H. Pathological features of coronary arteries in children with
Kawasaki disease in which coronary arterial aneurysm was absent at autopsy. Quantitative
analysis. Circulation 1988, 78, 345–350.
Naoe, S.; Takahashi, K.; Masuda, H.; Tanaka, N. Kawasaki disease. With particular emphasis on
arterial lesions. Acta Pathol. Jpn. 1991, 41, 785–797.
Takahashi, K.; Oharaseki, T.; Yokouchi, Y.; Yamada, H.; Shibuya, K.; Naoe, S. A half-century
of autopsy results—Incidence of pediatric vasculitis syndromes, especially Kawasaki disease
(in Chinese). Circ. J. 2012, 76, 964–970.
Gao, J.; Wang, H.-Y.; Wu, N.-J.; Zhang, S.-H. Relationship between fibrinogen Bβ-148C/T
polymorphism and coronary artery lesions in children with Kawasaki disease. Zhongguo Dang
Dai Er Ke Za Zhi 2010, 12, 518–520.
Sleeper, L.A.; Minich, L.L.; McCrindle, B.M.; Li, J.S.; Mason, W.; Colan, S.D.; Atz, A.M.;
Printz, B.F.; Baker, A.; Vetter, V.L.; et al. Evaluation of kawasaki disease risk-scoring systems
for intravenous immunoglobulin resistance. J. Pediatr. 2011, 158, 831–835.
Ishihara, H.; Izumida, N.; Hosaki, J. Criterion for early prediction of coronary artery involvement
by clinical manifestations in patients with Kawasaki disease. Bull. Tokyo Med. Dent. Univ. 1985,
32, 77–89.
Koren, G.; Lavi, S.; Rose, V.; Rowe, R. Kawasaki disease: Review of risk factors for coronary
aneurysms. J. Pediatr. 1986, 108, 388–392.
Nakano, H.; Ueda, K.; Saito, A.; Tsuchitani, Y.; Kawamori, J.; Miyake, T.; Yoshida, T. Scoring
method for identifying patients with Kawasaki disease at high risk of coronary artery aneurysms.
Am. J. Cardiol. 1986, 58, 739–742.
Nakano, M. Predictive factors of coronary aneurysm in Kawasaki disease—Correlation between
coronary arterial lesions and serum albumin, cholinesterase activity, prealbumin, retinol-binding
protein and immature neutrophils. Prog. Clin. Biol. Res. 1987, 250, 535–537.

Diagnostics 2013, 3

241

24. Iwasa, M.; Sugiyama, K.; Ando, T.; Nomura, H.; Katoh, T.; Wada, Y. Selection of high-risk
children for immunoglobulin therapy in Kawasaki disease. Prog. Clin. Biol. Res. 1987, 250,
543–544.
25. Ichida, F.; Fatica, N.S.; Engle, M.A.; O’Loughlin, J.E.; Klein, A.A.; Snyder, M.S.; Ehlers, K.H.;
Levin, A.R. Coronary artery involvement in Kawasaki Syndrome in Manhattan, New York: Risk
factors and role of aspirin. Pediatrics 1987, 80, 828–835.
26. Daniels, S.R.; Specker, B.; Capannari, T.E.; Schwartz, D.C.; Burke, M.J.; Kaplan, S. Correlates of
coronary artery aneurysm formation in patients with Kawasaki disease. Am. J. Dis. Child. 1987,
141, 205–207.
27. Lu, C.P.; Lee, W.J.; Ho, M.M.; Hwang, K.C. Risk factors of coronary arterial aneurysm in
Kawasaki disease. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1993, 34, 173–180.
28. Mori, M.; Imagawa, T.; Yasui, K.; Kanaya, A.; Yokota, S. Predictors of coronary artery lesions
after intravenous gamma-globulin treatment in Kawasaki disease. J. Pediatr. 2000, 137, 177–180.
29. Morikawa, Y.; Ohashi, Y.; Harada, K.; Asai, T.; Okawa, S.; Nagashima, M.; Katoh, T.; Baba, K.;
Furusho, K.; Okuni, M.; et al. Coronary risks after high-dose gamma-globulin in children with
Kawasaki disease. Pediatr. Int. 2000, 42, 464–469.
30. Nomura, Y.; Masuda, K.; Yoshinaga, M.; Sameshima, K.; Miyata, K. Patients diagnosed with
Kawasaki disease before the fifth day of illness have a higher risk of coronary artery aneurysm.
Pediatr. Int. 2002, 44, 353–357.
31. Nofech-Mozes, Y.; Garty, B.-Z. Thrombocytopenia in Kawasaki disease: A risk factor for the
development of coronary artery aneurysms. Pediatr. Hematol. Oncol. 2003, 20, 597–601.
32. Honkanen, V.E.A.; McCrindle, B.W.; Laxer, R.M.; Feldman, B.M.; Schneider, R.; Silverman, E.D.
Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease.
Pediatr. Cardiol. 2003, 24, 122–126.
33. Chaiyarak, K.; Durongpisitkul, K.; Atta, T.; Soongswang, J.; Laohaprasitiporn, D.; Nana, A.
Clinical manifestations of kawasaki disease: What are the significant parameters? Asian Pac. J.
Allergy Immunol. 2009, 27, 131–136.
34. Durongpisitkul, K.; Soongswang, J.; Laohaprasitiporn, D.; Nana, A.; Prachuabmoh, C.;
Kangkagate, C. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr. Cardiol.
2003, 24, 145–148.
35. Kim, T.; Choi, W.; Woo, C.-W.; Choi, B.; Lee, J.; Lee, K.; Son, C.; Lee, J. Predictive risk factors
for coronary artery abnormalities in Kawasaki disease. Eur. J. Pediatr. 2007, 166, 421–425.
36. Kim, J.-J.; Hong, Y.M.; Yun, S.W.; Han, M.K.; Lee, K.-Y.; Song, M.S.; Lee, H.-D.; Kim, D.S.;
Sohn, S.; Ha, K.-S.; et al. Assessment of risk factors for Korean children with Kawasaki disease.
Pediatr. Cardiol. 2011, 33, 513–520.
37. Kaneko, K.; Yoshimura, K.; Ohashi, A.; Kimata, T.; Shimo, T.; Tsuji, S. Prediction of the risk of
coronary arterial lesions in Kawasaki disease by brain natriuretic peptide. Pediatr. Cardiol. 2011,
32, 1106–1109.
38. Chen, J.; Liu, Y.; Liu, W.; Wu, Z. A meta-analysis of the biomarkers associated with coronary
artery lesions secondary to Kawasaki disease in Chinese children. J. Huazhong Univ. Sci.
Technol. (Med. Sci.) 2011, 31, 705–711.

Diagnostics 2013, 3

242

39. Tremoulet, A.H.; Jain, S.; Chandrasekar, D.; Sun, X.; Sato, Y.; Burns, J.C. Evolution of
laboratory values in patients with Kawasaki disease. Pediatr. Infect. Dis. J. 2011, 30, 1022–1026.
40. Caballero-Mora, F.J.; Alonso-Martín, B.; Tamariz-Martel-Moreno, A.; Cano-Fernández, J.;
Sánchez-Bayle, M. Kawasaki disease in 76 patients. Risk factors for coronary artery aneurysms.
An. Pediatr. (Barc.) 2011, 74, 232–238.
41. Weng, K.-P.; Hsieh, K.-S.; Huang, S.-H.; Ou, S.-F.; Ma, C.-Y.; Ho, T.-Y.; Lai, C.-R.; Ger, L.-P.
Clinical relevance of the risk factors for coronary artery lesions in Kawasaki disease. Kaohsiung
J. Med. Sci. 2012, 28, 23–29.
42. Burns, J.C.; Glode, M.P.; Clarke, S.H.; Wiggins, J., Jr.; Hathaway, W.E. Coagulopathy and
platelet activation in Kawasaki syndrome: Identification of patients at high risk for development
of coronary artery aneurysms. J. Pediatr. 1984, 105, 206–211.
43. Yu, H.-R.; Kuo, H.-C.; Huang, E.-Y.; Liang, C.-D.; Hwang, K.-P.; Lin, I.-C.; Sheen, J.-M.;
Wang, T.-J.; Wang, C.-L.; Yang, K.D. Plasma clusterin levels in predicting the occurrence of
coronary artery lesions in patients with Kawasaki disease. Pediatr. Cardiol. 2010, 31, 1151–1156.
44. Kuo, H.-C.; Yang, Y.-L.; Chuang, J.-H.; Tiao, M.-M.; Yu, H.-R.; Huang, L.-T.; Yang, K.D.;
Chang, W.-C.; Lee, C.-P.; Huang, Y.-H. Inflammation-induced hepcidin is associated with the
development of anemia and coronary artery lesions in Kawasaki disease. J. Clin. Immunol. 2012,
32, 746–752.
45. Hsieh, K.-S.; Lai, T.-J.; Hwang, Y.-T.; Lin, M.-W.; Weng, K.-P.; Chiu, Y.-T.; Ho, T.-Y.;
Chen, C.-S.; Shiue, Y.-L.; Hsiao, M.; et al. IL-10 promoter genetic polymorphisms and risk of
Kawasaki disease in Taiwan. Dis. Markers 2011, 30, 51–59.
46. Hsieh, Y.-Y.; Lin, Y.-J.; Chang, C.-C.; Chen, D.-Y.; Hsu, C.-M.; Wang, Y.-K.; Hsu, K.-H.;
Tsai, F.-J. Human lymphocyte antigen B-associated transcript 2, 3, and 5 polymorphisms and
haplotypes are associated with susceptibility of Kawasaki disease and coronary artery aneurysm.
J. Clin. Lab. Anal. 2010, 24, 262–268.
47. Huang, Y.-C.; Lin, Y.-J.; Chang, J.-S.; Chen, S.-Y.; Wan, L.; Sheu, J.J.-C.; Lai, C.-H.; Lin, C.-W.;
Liu, S.-P.; Chen, C.-P.; et al. Single nucleotide polymorphism rs2229634 in the ITPR3 gene is
associated with the risk of developing coronary artery aneurysm in children with Kawasaki
disease. Int. J. Immunogenet. 2010, 37, 439–443.
48. Kuo, H.-C.; Yang, K.D.; Juo, S.-H.H.; Liang, C.-D.; Chen, W.-C.; Wang, Y.-S.; Lee, C.-H.;
Hsi, E.; Yu, H.-R.; Woon, P.-Y.; et al. ITPKC single nucleotide polymorphism associated with the
Kawasaki disease in a Taiwanese population. PLoS One 2011, 6, doi:10.1371/journal.pone.0017370.
49. Mamtani, M.; Matsubara, T.; Shimizu, C.; Furukawa, S.; Akagi, T.; Onouchi, Y.; Hata, A.;
Fujino, A.; He, W.; Ahuja, S.K.; et al. Association of CCR2-CCR5 haplotypes and CCL3L1 copy
number with Kawasaki disease, coronary artery lesions, and IVIG responses in Japanese children.
PLoS One 2010, 5, doi: 10.1371/journal.pone.0011458.
50. Onouchi, Y. Identification of susceptibility genes for Kawasaki disease. Jpn. J. Clin. Immunol.
2010, 33, 73–80.
51. Onouchi, Y.; Suzuki, Y.; Suzuki, H.; Terai, M.; Yasukawa, K.; Hamada, H.; Suenaga, T.;
Honda, T.; Honda, A.; Kobayashi, H.; et al. ITPKC and CASP3 polymorphisms and risks for IVIG
unresponsiveness and coronary artery lesion formation in Kawasaki disease. Pharmacogenomics J.
2013, 13, 52–59.

Diagnostics 2013, 3

243

52. Hata, A.; Onouchi, Y. Susceptibility genes for Kawasaki disease: Toward implementation of
personalized medicine. J. Hum. Genet. 2009, 54, 67–73.
53. Khor, C.C.; Davila, S.; Shimizu, C.; Sheng, S.; Matsubara, T.; Suzuki, Y.; Newburger, J.W.;
Baker, A.; Burgner, D.; Breunis, W.; et al. Genome-wide linkage and association mapping
identify susceptibility alleles in ABCC4 for Kawasaki disease. J. Med. Genet. 2011, 48, 467–472.
54. Khor, C.C.; Davila, S.; Breunis, W.B.; Lee, Y.-C.; Shimizu, C.; Wright, V.J.; Yeung, R.S.M.;
Tan, D.E.K.; Sim, K.S.; Wang, J.J.; et al. Genome-wide association study identifies FCGR2A as a
susceptibility locus for Kawasaki disease. Nat. Genet. 2011, 43, 1241–1246.
55. Kim, S.K.; Kang, S.W.; Chung, J.-H.; Lee, J.S.; Park, H.K.; Yoon, K.L.; Kim, S.C. Coding
single-nucleotide polymorphisms of interleukin-1 gene cluster are not associated with Kawasaki
disease in the Korean population. Pediatr. Cardiol. 2011, 32, 381–385.
56. Masi, L.; Franceschelli, F.; Leoncini, G.; Gozzini, A.; Rigante, D.; La Torre, F.; Matucci-Cerinic, M.;
Brandi, M.L.; Falcini, F. Can fibroblast growth factor (FGF)-23 circulating levels suggest
coronary artery abnormalities in children with Kawasaki disease? Clin. Exp. Rheumatol. 2013, 31,
149–153.
57. Shimizu, C.; Jain, S.; Davila, S.; Hibberd, M.L.; Lin, K.O.; Molkara, D.; Frazer, J.R.; Sun, S.;
Baker, A.L.; Newburger, J.W.; et al. Transforming growth factor-β signaling pathway in patients
with Kawasaki disease. Circ. Cardiovasc. Genet. 2011, 4, 16–25.
58. Yamamura, K.; Ihara, K.; Ikeda, K.; Nagata, H.; Mizuno, Y.; Hara, T. Histo-blood group gene
polymorphisms as potential genetic modifiers of the development of coronary artery lesions in
patients with Kawasaki disease. Int. J. Immunogenet. 2012, 39, 119–125.
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).

